# Sofie Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sofie

- Industry: Pharmaceuticals
- Headquarters: Dulles, US
- Website: www.sofiebio.com
- Total disclosed funding: $7M
- Latest round: Series A (Oct 15, 2013)
- Investors on record: 3

## About

Founded in 2006 and based in Virginia, US, Sofie Co. is a molecular imaging company that provides radiopharmaceutical production and distribution services for the healthcare industry. In January 2024, Trilantic North America, along with the company's management, agreed to invest in Sofie Co. As of 2024, the company is headed by its CEO Patricks Phelps.

SOFIE Biosciences offers a suite of products and services including radiopharmaceuticals for PET imaging, contract manufacturing services, and educational programs for PET practices. The company's portfolio features radiotracers for diagnostics and therapeutics, aimed at diagnosing and treating critical illnesses. Their contract manufacturing services cater to clinical needs, and their educational initiatives aim to improve PET program quality.

The January 2024 investment may support Sofie Co. in implementing various growth strategies, expanding capacity and locations, and enhancing its radiopharmaceutical products.

## Funding rounds

- Series A, Oct 15, 2013, $5M — Cycad Group, Tata Sons Private Limited, MRM Capital
- Series A, Dec 8, 2010, $2M — Cycad Group

## Investors

- Cycad Group (https://capitalatlas.ai/funds/cycad-group) — Series A
- Tata Sons Private Limited — Series A
- MRM Capital — Series A